Clearmind Medicine Inc.
CMND · NASDAQ
10/31/2024 | 10/31/2023 | 10/31/2022 | 10/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $56 | $113 | $3 |
| Gross Profit | -$27 | -$56 | -$113 | -$3 |
| % Margin | – | – | – | – |
| R&D Expenses | $1,377 | $2,141 | $2,985 | $646 |
| G&A Expenses | $3,262 | $6,600 | $5,435 | $3,030 |
| SG&A Expenses | $4,353 | $6,600 | $5,435 | $3,030 |
| Sales & Mktg Exp. | $1,091 | $0 | $0 | $0 |
| Other Operating Expenses | $2,268 | $0 | $113 | $0 |
| Operating Expenses | $7,999 | $8,741 | $8,533 | $3,676 |
| Operating Income | -$7,999 | -$8,741 | -$8,533 | -$3,676 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $1,209 | -$3,190 | -$818 | -$44 |
| Pre-Tax Income | -$4,877 | -$11,931 | -$9,370 | -$3,720 |
| Tax Expense | $378 | $24 | $41 | $0 |
| Net Income | -$5,255 | -$11,955 | -$9,411 | -$3,720 |
| % Margin | – | – | – | – |
| EPS | -67.6 | -1,703.2 | -6,744.4 | -4,812 |
| % Growth | 96% | 74.7% | -40.2% | – |
| EPS Diluted | -67.6 | -1,703.2 | -8,688 | -4,812 |
| Weighted Avg Shares Out | 107 | 51 | 11 | 8 |
| Weighted Avg Shares Out Dil | 107 | 51 | 11 | 8 |
| Supplemental Information | – | – | – | – |
| Interest Income | $271 | $58 | $0 | $0 |
| Interest Expense | $36 | $0 | $20 | $0 |
| Depreciation & Amortization | $17 | $31 | $31 | $3 |
| EBITDA | -$7,982 | -$8,711 | -$8,486 | -$3,674 |
| % Margin | – | – | – | – |